<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Arrivent Biopharma, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock</link>
<description>Latest news and press releases for Arrivent Biopharma, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 21:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/arrivent-biopharma-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683549d078dffbe2df0e4692.webp</url>
<title>Arrivent Biopharma, Inc. Common Stock</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock</link>
</image>
<item>
<title>ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-to-present-two-preclinical-posters-on-the-egfr-inhibitor-firmonertinib-and-on-the-novel-dual-target-muc16napi2b-tetravalent-adc-arr-002-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-to-present-two-preclinical-posters-on-the-egfr-inhibitor-firmonertinib-and-on-the-novel-dual-target-muc16napi2b-tetravalent-adc-arr-002-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Tue, 17 Mar 2026 21:00:00 GMT</pubDate>
<description>Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable tolerability underscores best-in-disease ADC potential NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company</description>
</item>
<item>
<title>ArriVent BioPharma Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-full-year-2025-financial-results-30</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-full-year-2025-financial-results-30</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line</description>
</item>
<item>
<title>ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-first-patient-dosed-global-pivotal-phase-3-alpacca-trial</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-first-patient-dosed-global-pivotal-phase-3-alpacca-trial</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free</description>
</item>
<item>
<title>ArriVent BioPharma Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-third-quarter-2025-financial-results-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-third-quarter-2025-financial-results-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received</description>
</item>
<item>
<title>ArriVent Appoints Brent S. Rice as Chief Commercial Officer</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-appoints-brent-s-rice-chief-commercial-officer-2025-09-22</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-appoints-brent-s-rice-chief-commercial-officer-2025-09-22</guid>
<pubDate>Mon, 22 Sep 2025 04:00:00 GMT</pubDate>
<description>NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to</description>
</item>
<item>
<title>Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-presents-final-analysis-firmonertinib-monotherapy-data-global-phase-1b-study</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-presents-final-analysis-firmonertinib-monotherapy-data-global-phase-1b-study</guid>
<pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
<description>16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed</description>
</item>
<item>
<title>ArriVent BioPharma Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-second-quarter-2025-financial-results-2025-08-11</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-second-quarter-2025-financial-results-2025-08-11</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll</description>
</item>
<item>
<title>ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivents-topline-pivotal-phase-3-furvent-data-firmonertinib-first-line-nsclc-egfr</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivents-topline-pivotal-phase-3-furvent-data-firmonertinib-first-line-nsclc-egfr</guid>
<pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
<description>Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa.,</description>
</item>
<item>
<title>ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-pricing-75-million-public-offering-common-stock-and-pre-funded</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-pricing-75-million-public-offering-common-stock-and-pre-funded</guid>
<pubDate>Tue, 01 Jul 2025 04:00:00 GMT</pubDate>
<description>NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to</description>
</item>
<item>
<title>ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-proposed-75-million-public-offering-common-stock-and-pre-funded</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-proposed-75-million-public-offering-common-stock-and-pre-funded</guid>
<pubDate>Tue, 01 Jul 2025 04:00:00 GMT</pubDate>
<description>NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to</description>
</item>
<item>
<title>ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-positive-interim-firmonertinib-monotherapy-data-global-phase-1b</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-positive-interim-firmonertinib-monotherapy-data-global-phase-1b</guid>
<pubDate>Mon, 23 Jun 2025 04:00:00 GMT</pubDate>
<description>16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust</description>
</item>
<item>
<title>ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-investor-event-firmonertinib-path-forward-egfr-pacc-mutant-nsclc</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-investor-event-firmonertinib-path-forward-egfr-pacc-mutant-nsclc</guid>
<pubDate>Fri, 20 Jun 2025 04:00:00 GMT</pubDate>
<description>Virtual webinar on June 23, 2025 at 8:00 am ET NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq:</description>
</item>
<item>
<title>ArriVent BioPharma Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-first-quarter-2025-financial-results-2025-05-12</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-first-quarter-2025-financial-results-2025-05-12</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned</description>
</item>
<item>
<title>ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-appoints-merdad-parsey-md-phd-its-board-directors-2025-04-28</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-appoints-merdad-parsey-md-phd-its-board-directors-2025-04-28</guid>
<pubDate>Mon, 28 Apr 2025 04:00:00 GMT</pubDate>
<description>NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to</description>
</item>
<item>
<title>ArriVent BioPharma Reports Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-full-year-2024-financial-results-2025-03-03</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-full-year-2024-financial-results-2025-03-03</guid>
<pubDate>Mon, 03 Mar 2025 05:00:00 GMT</pubDate>
<description>First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal</description>
</item>
<item>
<title>ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-enters-exclusive-license-lepu-biopharma-mrg007-antibody-drug</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-enters-exclusive-license-lepu-biopharma-mrg007-antibody-drug</guid>
<pubDate>Tue, 21 Jan 2025 05:00:00 GMT</pubDate>
<description>Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancersFirst</description>
</item>
<item>
<title>ArriVent BioPharma Reports Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-third-quarter-2024-financial-results-2024-11-14</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-third-quarter-2024-financial-results-2024-11-14</guid>
<pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
<description>Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global</description>
</item>
<item>
<title>ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-positive-proof-concept-global-phase-1b-interim-data-firmonertinib</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-announces-positive-proof-concept-global-phase-1b-interim-data-firmonertinib</guid>
<pubDate>Mon, 09 Sep 2024 04:00:00 GMT</pubDate>
<description>81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed</description>
</item>
<item>
<title>ArriVent BioPharma Reports Second Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-second-quarter-2024-financial-results-2024-08-14</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-biopharma-reports-second-quarter-2024-financial-results-2024-08-14</guid>
<pubDate>Wed, 14 Aug 2024 04:00:00 GMT</pubDate>
<description>Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as</description>
</item>
<item>
<title>ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer</title>
<link>https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-present-proof-concept-phase-1b-data-firmonertinib-egfr-pacc-mutant-non-small</link>
<guid isPermaLink="true">https://6ix.com/company/arrivent-biopharma-inc-common-stock/news/arrivent-present-proof-concept-phase-1b-data-firmonertinib-egfr-pacc-mutant-non-small</guid>
<pubDate>Mon, 12 Aug 2024 04:00:00 GMT</pubDate>
<description>First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session First prospectively designed randomized</description>
</item>
</channel>
</rss>